Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Susan R. Wiersma"'
Autor:
Andrew Schumacher, Lawrence W. Anderson, Kayla Rosati, Jerry M. Collins, Thomas A. DiPetrillo, Timothy J. Kinsella, Howard Safran, Kimberly D. Hill, John Vatkevich, Charles A. Kunos, Susan R Wiersma
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(20)
Purpose: Iododeoxyuridine (IUdR) is a potent radiosensitizer; however, its clinical utility is limited by dose-limiting systemic toxicities and the need for prolonged continuous infusion. 5-Iodo-2-pyrimidinone-2′-deoxyribose (IPdR) is an oral prodr
Autor:
Katharine A. Downes, Susan R. Wiersma, Claire McGrath, Roslyn Yomtovian, Girish Sharma, Suneeti Sapatnekar
Publikováno v:
Journal of Clinical Apheresis. 20:225-229
The practice of transfusing ABO-incompatible platelets, driven primarily by concerns about inventory management, has been considered generally safe because the accompanying plasma is usually diluted in the recipient's total blood volume. However, if
Publikováno v:
Pediatric and Developmental Pathology. 7:71-76
This is the second reported patient with systemic juvenile xanthogranuloma (JXG) to die with liver failure. The infant was born with multiple skin lesions and mild hepatomegaly. Direct hyperbilirubinemia was noted on the 2nd day of life, followed by
Autor:
Susan R. Wiersma, Gregory H. Reaman, Mark Krailo, Wen Liu-Mares, Patricia A. Dinndorf, Vassilios I. Avramis, J F Kelleher, Revonda B. Mosher, Judith K. Sato, Nita L. Seibel
Publikováno v:
Journal of Clinical Oncology. 15:2780-2785
PURPOSE The Children's Cancer Group (CCG) undertook a phase I study (CCG-0922) to determine a tolerable dose of idarubicin given with fludarabine and cytarabine in children with relapsed or refractory leukemia. The phase I study was extended to a lim
Autor:
Nidal Mahgoub, J. Russell Geyer, Kevin M. Shannon, John M. Maris, B S Patricia Thompson, Beverly J. Lange, Susan R. Wiersma, Carole G. H. Hurwitz
Publikováno v:
Cancer. 79:1438-1446
BACKGROUND Children with neurofibromatosis type 1 (NF1) are at increased risk of developing benign and malignant solid tumors as well as hematologic malignancies, including de novo juvenile chronic myelogenous leukemia, monosomy 7 syndrome, and acute
Autor:
Susan R. Wiersma, Jami D. Frost
Publikováno v:
Journal of Pediatric Hematology/Oncology. 18:396-400
Purpose: We describe successful treatment of an infant with progressive Langerhans cell histiocytosis (LCH) with allogeneic bone marrow transplantation (BMT), and discuss a chromosomal abnormality discovered in his LCH-affected tissue. Patients and M
Publikováno v:
Journal of pediatric hematology/oncology. 33(8)
Here we report a 3-year-old boy with myelomastocytic leukemia. The patient presented with fatigue and right eye proptosis. Bone marrow revealed acute myeloid leukemia with t(8;21) and trisomy 8. Induction therapy produced marked reduction in marrow m
Autor:
Kiyoshi Takatsuki, Akihiro Shimosaka, Jorge A. Ortega, Vita J. Land, Teresa J. Vietti, Hiroyuki Tsuchiya, Susan R. Wiersma, Michael J. Schell, Gaston K. Rivera, William M. Crist, Masahiko Watanabe, Kenneth I. Weinberg, Ichiro Matsuda, Eugene Sobel, Jonathan J. Shuster, David R. Head, Susana C. Raimondi, Michael J. Borowitz, Ching-Hon Pui, Norio Asou, Frederick G. Behm, C. Philip Steuber, D. Jeanette Pullen
Publikováno v:
New England Journal of Medicine. 325:1378-1382
Publikováno v:
Drugs. 42:766-780
Wilms' tumour (nephroblastoma, renal embryoma) is the fifth most common paediatric malignancy, arising from the embryonal tissue of kidneys and first formally described by Max Wilms in his classic 1899 monograph. Until the early part of this century,
Autor:
Mark Krailo, Gregory H. Reaman, Revonda B. Mosher, Matthew M. Ames, Susan R. Wiersma, Wen Lieu Mares, Joel M. Reid, Nita L. Seibel, Robert J. Wells
Publikováno v:
Journal of pediatric hematology/oncology. 24(2)
Objectives: To determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of cisplatin after a 72-hour continuous infusion of topotecan. Patients and Methods: Thirty-six children younger than age 22 years (range 3-21) with recurre